Other: Saline solution ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
67	Polycystic kidney disease	2

67. Polycystic kidney disease

---

Clinical trials : 216 /  Drugs : 219 - (DrugBank : 50) / Drug target genes : 39 - Drug target pathways : 151

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01377246 (ClinicalTrials.gov)	May 2011	20/6/2011	Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED CLINICAL TRIAL TO ASSESS THE EFFECTS OF LONG-ACTING SOMATOSTATIN (OCTREOTIDE LAR) THERAPY ON DISEASE PROGRESSION IN PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE AND MODERATE TO SEVERE RENAL INSUFFICIENCY	Autosomal Dominant Polycystic Kidney Disease	Drug: Octreotide-LAR;Other: Saline solution.	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	75 Years	All	100	Phase 3	Italy
2	NCT00309283 (ClinicalTrials.gov)	April 2006	30/3/2006	Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study	Effect of a Long-acting Somatostatin on Disease Progression in Nephropathy Due to Autosomal Dominant Polycystic Kidney Disease: a Long-term Three Year Follow up Study	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	Drug: Long-acting somatostatin;Other: Saline solution	Mario Negri Institute for Pharmacological Research	NULL	Completed	18 Years	75 Years	Both	78	Phase 3	Italy